Navigation Links
FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol
Date:8/14/2014

BRIDGEWATER, N.J., Aug. 14, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced the U.S. Food and Drug Administration (FDA) has agreed with the design of our pivotal Phase III protocol for Neutrolin® in Hemodialysis patients, and the company plans to submit the IND for Neutrolin within the next 30 days. The FDA will then have 30 days to respond to the IND.  The pivotal Phase 3 randomized controlled trial ("RCT") for Neutrolin is for use in hemodialysis patients with a central venous catheter.  The Phase 3 clinical trial will be a multi-center, randomized, controlled study conducted in the U.S. and Europe.  Dr. Michael Allon, Professor, Department of Medicine, Division of Nephrology, University of Alabama, Birmingham will be the Study Chair of the Neutrolin Phase 3 program.

In addition, CorMedix is pleased to announce strategic business collaboration with Wonik Corporation, a South Korean corporation with a strong medical device franchise within the Korean healthcare market.  Wonik has a strong medical franchise and we believe it is well positioned to market, sell and distribute Neutrolin for hemodialysis patients upon receipt of regulatory approval in Korea.

Randy Milby, Chief Executive Officer of CorMedix, stated, "I am very pleased to have signed a definitive agreement with an established commercial partner, Wonik Group in South Korea, a professional and growing healthcare company in one of the key markets in East Asia.  It will of course take some time to gain regulatory approval to market the product."

"In addition, the acceptance of the Neutrolin pivotal Phase 3 clinical trial protocol is a major milestone which provide
'/>"/>

SOURCE CorMedix Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Accepts Tasimelteon New Drug Application For Priority Review In The Treatment Of Non-24-Hour Disorder In The Totally Blind
2. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
3. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
4. FDA Accepts Novens NDA For An Investigational Nonhormonal Therapy For Menopausal Vasomotor Symptoms
5. Pivotal Therapeutics To Explore Potential Commercial Partnership Opportunities in China
6. KindredBio Schedules Release of 2014 Second Quarter Financial Results and Provides Timeline for Release of CereKin Pivotal Study Data
7. BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy
8. Pelvalon Announces Results from the LIFE Pivotal Trial at the 2014 AUGS/IUGA Conference
9. Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer
10. Shield Therapeutics ST10 Delivers Robust Results Meeting both Primary and Secondary Endpoints in the Pivotal AEGIS Phase 3 Programme for the Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease
11. FDA Grants Approval of IND to Commence a Phase 3 Pivotal Study for ST10 for the Treatment of Iron Deficiency Anaemia in Chronic Kidney Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... June 2, 2015 The Canadian Society for Vascular ... tests, treatments or procedures that are commonly ordered ... part of Choosing Wisely Canada.  The list identifies ... conversations between patients and physicians about what care ... for Vascular Surgery,s list identified the following five ...
(Date:6/2/2015)... FORT WORTH, Texas , June 2, 2015 ... simulation market report defines and segments the concerned ... market was valued at $261.8 million in 2014, ... 2019, at a CAGR of 19.3% from 2014 ... of North America Mannequin-Based Simulation Market for an ...
(Date:6/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/g5r2nj/surgical_incision ) has announced ... Strategic Business Report" report to their offering. ... Canada , Japan , ... Latin America , and Rest of World. ... Closures in US$ Million by the following Product Segments: Stapler ...
Breaking Medicine Technology:As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 2As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 3As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 4North America Mannequin-Based Simulation Market is Expected to Reach $632.5 Million by 2019, at a CAGR of 19.3% From 2014 to 2019 2North America Mannequin-Based Simulation Market is Expected to Reach $632.5 Million by 2019, at a CAGR of 19.3% From 2014 to 2019 3Surgical Incision Closures - Global Strategic Business Report 2015 2
(Date:6/2/2015)... June 02, 2015 Glidewell Laboratories, ... announced today that the new issue of Chairside® ... print and online. The digital edition of the ... as past issues of the dental laboratory’s magazine, ... and smartphone platforms by visiting http://www.chairsidemagazine.com . ...
(Date:6/2/2015)... New Jersey (PRWEB) June 02, 2015 ... Jersey’s largest nonprofit provider of home health care, ... of its President and CEO, Steve Landers, MD, ... (VNAA) Board of Directors. , VNAA is ... supports, promotes and advances mission driven, nonprofit providers ...
(Date:6/2/2015)... June 02, 2015 Residents of Monarch ... walk…or swim, take a fitness class, do yoga, play ... In preparation for the Alzheimer’s Association’s Walk to ... staff will take part in a challenge to exercise ... Monarch Landing’s management company. , While the walk will ...
(Date:6/2/2015)... 2015 Mercy Health (formerly Catholic Health ... Kentucky – has devoted the seventh of its monthly ... cancer prevention. One in five Americans will get skin ... YouTube channel, a Mercy Health expert addresses these skin ... causes of skin cancer? ,     What are the ...
(Date:6/2/2015)... Consumer Reports, the world’s largest ... its commitment to help wipe out antibiotic-resistant bacteria ... antibiotics sicken about 2.25 million Americans each year ... Disease Control and Prevention. , The initiative kicks ... Tellado participating in the White House Forum on ...
Breaking Medicine News(10 mins):Health News:Glidewell Laboratories Releases New Issue of Restorative Dentistry Magazine Chairside in Print and Online 2Health News:Glidewell Laboratories Releases New Issue of Restorative Dentistry Magazine Chairside in Print and Online 3Health News:Steve Landers, MD, MPH, President and CEO of VNA Health Group Appointed to VNAA Board of Directors 2Health News:Steve Landers, MD, MPH, President and CEO of VNA Health Group Appointed to VNAA Board of Directors 3Health News:Monarch Landing Takes 60-Day Exercise Challenge to Combat Alzheimer’s 2Health News:Monarch Landing Takes 60-Day Exercise Challenge to Combat Alzheimer’s 3Health News:Video provides helpful information about skin cancer prevention 2Health News:Consumer Reports Aims to Stop the Spread of Superbugs 2Health News:Consumer Reports Aims to Stop the Spread of Superbugs 3
... mobile technology for global health also launched at GSM conference ... ... 17, 2009 -- Three of the world,s leading foundations involved ... United Nations Foundation and The Vodafone Foundation--announced today at GSMA,s ...
... Group Net LLC, a company dedicated to getting pharmaceutical companies more ... has released its 2008 savings results for the YourRxCard free prescription ... 2009 and recent accomplishments from www.PatientAssistance.com , privately funded by ... ...
... Treating NSCLC, Says Report in "The Oncologist"DURHAM, N.C., ... histology, improves treatment decisions that may lead to ... cancer (NSCLC), the most common type of lung ... issue of "The Oncologist."(Logo: http://www.newscom.com/cgi-bin/prnh/20080627/CLF051LOGO ...
... Dr. John S. Findley, president of the ... today for introducing a federal bill aimed at ... where teeth can become blackened, stained, rotting and ... Sen. Max Baucus (D-Mont.) introduced the bill on ...
... researchers say , , MONDAY, Feb. 16 (HealthDay News) -- People ... to develop Parkinson,s disease, a new study finds. , While ... have shown that people with Parkinson,s diseases are at greater ... member with melanoma, they may be at risk for Parkinson,s ...
... New research has shown that 78 percent of ... resources to maximize growth potential for post-launch activities. As ... physicians, finding the right way to time, build and ... products success and company profit levels. Many organizations wonder ...
Cached Medicine News:Health News:Leading Foundations to Form mHealth Alliance 2Health News:Leading Foundations to Form mHealth Alliance 3Health News:Leading Foundations to Form mHealth Alliance 4Health News:Patient Savings on Prescription Drugs Reach Record High for 2008, Goal Announced for 2009 2Health News:Patient Savings on Prescription Drugs Reach Record High for 2008, Goal Announced for 2009 3Health News:Patient Savings on Prescription Drugs Reach Record High for 2008, Goal Announced for 2009 4Health News:Patient Savings on Prescription Drugs Reach Record High for 2008, Goal Announced for 2009 5Health News:Patient Savings on Prescription Drugs Reach Record High for 2008, Goal Announced for 2009 6Health News:Lung Cancer Microscopic Appearance Affects Response to Chemotherapy 2Health News:Lung Cancer Microscopic Appearance Affects Response to Chemotherapy 3Health News:American Dental Association Applauds Legislators for Introducing 'Meth Mouth' Bill 2Health News:Family History of Melanoma Doubles Parkinson's Risk 2Health News:New Study Shares Benchmarks for Medical Science Liaisons: Gaining Access and Forging Relationships with Key Opinion Leaders 2
... is a solid solution for ... package includes the Vibratome Plus, ... blocks, v-block adapter, specimen mounts ... stage assembly for ease in ...
... Vibratome Semi-Automatic Tissue Sectioning System has maintained ... sectioning system. Researchers from around the globe ... for their fresh and fresh fixed tissue ... With the Vibratome Automatic Tissue Sectioning ...
... The NEW Vibratome 3000 Plus Sectioning ... fresh or fixed, animal, or plant tissues. ... principle which allows sectioning without freezing or ... alteration of morphology, the destruction of enzyme ...
... NEW Vibratome 3000 Plus Sectioning System provides ... fixed, animal, or plant tissues. The ... allows sectioning without freezing or embedding. ... morphology, the destruction of enzyme activities, and ...
Medicine Products: